Bailey CJ, et al. - In this review, researchers analyzed recent randomized controlled cardiovascular (CV) outcome trials with glucose-lowering therapies and their impact on the treatment of patients with type 2 diabetes. The data presented in this work showed a large proportion of patients recruited into these trials have previously experienced adverse CV events. The findings from the present study suggested that new glucose-lowering medications did not adversely affect CV events, and some of these agents might protect against CV events.